Product Revenue

- AYVAKIT/AYVAKYT Sales

Collaboration and License Revenue

- Rigel Agreement

- CStone Collaboration

- Roche Pralsetinib Collaboration

- Other

- License Revenue - Related Party

Total Revenue

32cf0bb9734f70299364e15d7dd85beea14859adfe5aa8427c345cfab5b8b1ec

Net Loss (USD, thousands)

Depreciation and Amortization (USD, thousands)

Non-cash Lease Expense (USD, thousands)

Stock-based Compensation (USD, thousands)

Non-cash Interest Expense (USD, thousands)

Non-cash Debt Extinguishment Gain (USD, thousands)

Net (Accretion of Discount) Amortization of Premium on Investments (USD, thousands)

Other Adjustments to Net Loss (USD, thousands)

Accounts Receivable Change (USD, thousands)

Unbilled Accounts Receivable Change (USD, thousands)

Inventory Change (USD, thousands)

Prepaid Expenses and Other Current Assets Change (USD, thousands)

Other Assets Change (USD, thousands)

Accounts Payable Change (USD, thousands)

Accrued Expenses Change (USD, thousands)

Other Long Term Liabilities Change (USD, thousands)

Deferred Revenue Change (USD, thousands)

Operating Lease Liabilities Change (USD, thousands)

Net Cash Used in Operating Activities (USD, thousands)

Purchases of Property and Equipment (USD, thousands)

Purchases of Investments (USD, thousands)

Maturities of Investments (USD, thousands)

Net Cash Provided by (Used in) Investing Activities (USD, thousands)

Proceeds from At-The-Market Offerings, Net of Issuance Costs (USD, thousands)

Net Proceeds from Stock Option Exercises and Employee Stock Purchase Plan (USD, thousands)

Net Proceeds from Term Loan Facility (USD, thousands)

Principle Payments for Financing Arrangements (USD, thousands)

Net Cash Provided by Financing Activities (USD, thousands)

Net Increase (Decrease) in Cash, Cash Equivalents, and Restricted Cash (USD, thousands)

Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash (USD, thousands)

Cash Paid for Interest (USD, thousands)

Cash Paid (Refunds Received) for Taxes, Net (USD, thousands)

Cash, Cash Equivalents and Restricted Cash at Beginning of Period (USD, thousands)

Cash, Cash Equivalents and Restricted Cash at End of Period (USD, thousands)

Property and Equipment Purchases Unpaid at Period End (USD, thousands)

d3844108ec542e97e97737bedea629fffe214e2ba162001fd965383cd94b3aea

Product Revenue, Net (USD, thousands)

Collaboration and License Revenue (USD, thousands)

Total Revenues (USD, thousands)

Cost of Sales (USD, thousands)

Research and Development Expenses (USD, thousands)

Selling, General and Administrative Expenses (USD, thousands)

Total Cost and Operating Expenses (USD, thousands)

Interest Income (Expense), Net (USD, thousands)

Other Income (Expense), Net (USD, thousands)

Total Other Income (Expense) (USD, thousands)

Loss Before Income Taxes (USD, thousands)

Income Tax Expense (USD, thousands)

Net Loss per Share - Basic and Diluted (USD)

Weighted-Average Number of Common Shares Used in Net Loss per Share - Basic and Diluted (thousands)

6a7c5b011717c2576b08960ba78e5546803dcf23802d5b7ca39fc57468897d56

United States

- Rest of World

Collaboration/Other

- Roche Collaboration

- Other Collaboration

966a87368976dde3fbb70a5b29a8acbaa82d2eb569f7bf3550549d2c2d68b2f7

Cash and cash equivalents (USD, thousands)

Marketable securities - current assets (USD, thousands)

Marketable securities - non-current assets (USD, thousands)

Total assets (USD, thousands)

Current portion of deferred revenue (USD, thousands)

Current portion of liabilities related to the sale of future royalties and revenues (USD, thousands)

Current portion of term loan (USD, thousands)

Deferred revenue, net of current portion (USD, thousands)

Liabilities related to the sale of future royalties and revenues, net of current portion (USD, thousands)

Term loan, net of current portion (USD, thousands)

Total liabilities (USD, thousands)

Total stockholders’ equity (USD, thousands)

c565023422e70265edbf26f84c4db131a32dfcccf74253f9adf5115a5df7b4cf

Blueprint Medicines Corp (BPMC)

Financials